View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioservo Technologies 将来の成長Future 基準チェック /26 Bioservo Technologiesは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長21.4%収益成長率69.3%将来の株主資本利益率6.36%アナリストカバレッジLow最終更新日08 Nov 2023今後の成長に関する最新情報Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.すべての更新を表示Recent updatesお知らせ • Jan 05Bioservo to Be Delisted from Nasdaq First NorthNasdaq has decided to approve Bioservo Technologies AB (publ)'s application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024.お知らせ • Dec 15Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth MarketAt the extraordinary general meeting held in Bioservo Technologies AB (publ) (the "Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator. Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press release shortly after the Company has received confirmation from Nasdaq First North.New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (200% increase in shares outstanding). Market cap is less than US$10m (kr5.32m market cap, or US$509.5k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr52m). Revenue is less than US$5m (kr12m revenue, or US$1.1m).Reported Earnings • Nov 08Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.47m (up 31% from 3Q 2022). Net loss: kr9.76m (loss narrowed 8.9% from 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.お知らせ • Sep 27Bioservo Technologies AB (publ) Appoints Annika Rydgård as A New Member of the Management TeamBioservo Technologies AB (publ) announced appointment of Annika Rydgård as a new member of the management team, responsible for clinical projects and Market Access.Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.45m (down 72% from 2Q 2022). Net loss: kr11.9m (loss widened 1.1% from 2Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden.お知らせ • Jul 07Bioservo Technologies AB (Publ) Announces Chief Financial Officer ChangesBioservo Technologies AB (publ) announced that the company has contracted Michael Forss as new interim CFO and member of the management team. Michael succeeds Madeleine Börjesson as CFO and will take up the position on July 7, 2023. Michael has a background as an auditor and partner at EY with long and valuable experience of public companies in an international environment. Since 2019, Michael works in his own consulting company with advice in financial accounting, reporting and business management. Bioservo would like to take the opportunity to thank resigning CFO Madeleine Börjesson for her valuable contribution to the company and wish her all the best in the future.New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 350% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Market cap is less than US$10m (kr55.8m market cap, or US$5.24m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).Reported Earnings • Apr 26First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr4.94m (up 18% from 1Q 2022). Net loss: kr9.38m (loss narrowed 23% from 1Q 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 22Full year 2022 earnings released: kr2.66 loss per share (vs kr2.09 loss in FY 2021)Full year 2022 results: kr2.66 loss per share (further deteriorated from kr2.09 loss in FY 2021). Revenue: kr14.8m (up 41% from FY 2021). Net loss: kr50.5m (loss widened 46% from FY 2021). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 20Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr3.42m (down 39% from 3Q 2021). Net loss: kr10.7m (loss widened 70% from 3Q 2021). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Sweden.Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.Reported Earnings • Sep 01Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.15m (up 403% from 2Q 2021). Net loss: kr11.8m (loss widened 8.2% from 2Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 146% growth forecast for the Medical Equipment industry in Sweden.Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr4.20m (up 91% from 1Q 2021). Net loss: kr12.1m (loss widened 35% from 1Q 2021). Over the next year, revenue is forecast to grow 113%, compared to a 104% growth forecast for the industry in Sweden.Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.83 loss per share (down from kr1.82 loss in FY 2020). Revenue: kr11.9m (down 16% from FY 2020). Net loss: kr34.7m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 1.6%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 10Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr5.59m (up 54% from 3Q 2020). Net loss: kr6.30m (loss widened 8.5% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 02Chairman of the Board recently bought kr149k worth of stockOn the 31st of August, Anders Lundmark bought around 13k shares on-market at roughly kr11.70 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.分析記事 • Sep 01Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • Aug 13Second quarter 2021 earnings releasedThe company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.02m (down 76% from 2Q 2020). Net loss: kr10.9m (loss widened 125% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • May 05First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr2.19m (up 25% from 1Q 2020). Net loss: kr8.99m (loss widened 19% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Apr 11Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Mar 11New 90-day low: kr13.80The company is down 21% from its price of kr17.50 on 11 December 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.Reported Earnings • Feb 25Full year 2020 earnings released: kr1.82 loss per share (vs kr2.35 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr11.7m (down 51% from FY 2019). Net loss: kr26.3m (loss widened 13% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Dec 28New 90-day high: kr17.65The company is up 42% from its price of kr12.40 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.分析記事 • Dec 27We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Dec 11New 90-day high: kr14.70The company is up 27% from its price of kr11.60 on 11 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: kr10.35The company is down 22% from its price of kr13.35 on 26 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: kr11.35The company is down 9.0% from its price of kr12.50 on 28 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period.業績と収益の成長予測OM:BIOS - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202558N/A26112/31/202432N/A-15-13112/31/202315N/A-39-3819/30/202312-47-52-51N/A6/30/202311-48-51-51N/A3/31/202315-48-52-51N/A12/31/202214-50-52-51N/A9/30/202215-43-48-46N/A6/30/202217-39-40-38N/A3/31/202213-38-41-39N/A12/31/202111-35-36-34N/A9/30/20217-34-30-29N/A6/30/20215-34-24-23N/A3/31/202110-28-19-18N/A12/31/202014-26-18-17N/A9/30/202022-25-26-25N/A6/30/202023-24-24-23N/A3/31/202025-25-25-24N/A12/31/201924-23-27-26N/A9/30/201923-27-22-21N/A6/30/201921-28-32-29N/A3/31/201917-27-22-19N/A12/31/201816-28-22-17N/A9/30/201815-23-22-17N/A6/30/201814-21-18-13N/A3/31/201812-22-29-23N/A12/31/201712-19-22-16N/A9/30/201711-17-21-15N/A6/30/201711-16N/A-14N/A3/31/201712-12N/A-9N/A12/31/201611-13N/A-13N/A12/31/201511-7N/AN/AN/A12/31/20148-4N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOSの予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOSの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOSの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOSの収益 ( 69.3% ) Swedish市場 ( -0.3% ) よりも速いペースで成長すると予測されています。高い収益成長: BIOSの収益 ( 69.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOSの 自己資本利益率 は、3年後には低くなると予測されています ( 6.4 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/12 11:34終値2024/01/12 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioservo Technologies AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Mats HyttingeCarlsquare ABMats HyttingeRedeye
Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.
お知らせ • Jan 05Bioservo to Be Delisted from Nasdaq First NorthNasdaq has decided to approve Bioservo Technologies AB (publ)'s application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024.
お知らせ • Dec 15Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth MarketAt the extraordinary general meeting held in Bioservo Technologies AB (publ) (the "Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator. Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press release shortly after the Company has received confirmation from Nasdaq First North.
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (200% increase in shares outstanding). Market cap is less than US$10m (kr5.32m market cap, or US$509.5k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr52m). Revenue is less than US$5m (kr12m revenue, or US$1.1m).
Reported Earnings • Nov 08Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.47m (up 31% from 3Q 2022). Net loss: kr9.76m (loss narrowed 8.9% from 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.
お知らせ • Sep 27Bioservo Technologies AB (publ) Appoints Annika Rydgård as A New Member of the Management TeamBioservo Technologies AB (publ) announced appointment of Annika Rydgård as a new member of the management team, responsible for clinical projects and Market Access.
Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.45m (down 72% from 2Q 2022). Net loss: kr11.9m (loss widened 1.1% from 2Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden.
お知らせ • Jul 07Bioservo Technologies AB (Publ) Announces Chief Financial Officer ChangesBioservo Technologies AB (publ) announced that the company has contracted Michael Forss as new interim CFO and member of the management team. Michael succeeds Madeleine Börjesson as CFO and will take up the position on July 7, 2023. Michael has a background as an auditor and partner at EY with long and valuable experience of public companies in an international environment. Since 2019, Michael works in his own consulting company with advice in financial accounting, reporting and business management. Bioservo would like to take the opportunity to thank resigning CFO Madeleine Börjesson for her valuable contribution to the company and wish her all the best in the future.
New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 350% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Market cap is less than US$10m (kr55.8m market cap, or US$5.24m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).
Reported Earnings • Apr 26First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr4.94m (up 18% from 1Q 2022). Net loss: kr9.38m (loss narrowed 23% from 1Q 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 22Full year 2022 earnings released: kr2.66 loss per share (vs kr2.09 loss in FY 2021)Full year 2022 results: kr2.66 loss per share (further deteriorated from kr2.09 loss in FY 2021). Revenue: kr14.8m (up 41% from FY 2021). Net loss: kr50.5m (loss widened 46% from FY 2021). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 20Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr3.42m (down 39% from 3Q 2021). Net loss: kr10.7m (loss widened 70% from 3Q 2021). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Sweden.
Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.
Reported Earnings • Sep 01Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.15m (up 403% from 2Q 2021). Net loss: kr11.8m (loss widened 8.2% from 2Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 146% growth forecast for the Medical Equipment industry in Sweden.
Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr4.20m (up 91% from 1Q 2021). Net loss: kr12.1m (loss widened 35% from 1Q 2021). Over the next year, revenue is forecast to grow 113%, compared to a 104% growth forecast for the industry in Sweden.
Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.83 loss per share (down from kr1.82 loss in FY 2020). Revenue: kr11.9m (down 16% from FY 2020). Net loss: kr34.7m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 1.6%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 10Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr5.59m (up 54% from 3Q 2020). Net loss: kr6.30m (loss widened 8.5% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 02Chairman of the Board recently bought kr149k worth of stockOn the 31st of August, Anders Lundmark bought around 13k shares on-market at roughly kr11.70 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.
分析記事 • Sep 01Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • Aug 13Second quarter 2021 earnings releasedThe company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.02m (down 76% from 2Q 2020). Net loss: kr10.9m (loss widened 125% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • May 05First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr2.19m (up 25% from 1Q 2020). Net loss: kr8.99m (loss widened 19% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Apr 11Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Mar 11New 90-day low: kr13.80The company is down 21% from its price of kr17.50 on 11 December 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.
Reported Earnings • Feb 25Full year 2020 earnings released: kr1.82 loss per share (vs kr2.35 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr11.7m (down 51% from FY 2019). Net loss: kr26.3m (loss widened 13% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Dec 28New 90-day high: kr17.65The company is up 42% from its price of kr12.40 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
分析記事 • Dec 27We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Dec 11New 90-day high: kr14.70The company is up 27% from its price of kr11.60 on 11 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: kr10.35The company is down 22% from its price of kr13.35 on 26 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: kr11.35The company is down 9.0% from its price of kr12.50 on 28 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period.